• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans
  • .org
  • Districts
  • Media
  • SupportUs
  • Collaborate
  • Contact
  • Search
  • Join


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

Started by caliban , Mar 25 2011 01:11 AM
economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#91 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 23 November 2011 - 12:05 AM

How big a blow was Geron’s bombshell that it is bailing on embryonic stem cell research? BIG.
Lifesite - 2 hours ago
by Jill Stanek November 22, 2011 (JillStanek.com) - Out of nowhere the Geron Corporation announced last week it was not only halting the first clinical trial of embryonic stem cell treatment on ...

View the full article

#92 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 23 November 2011 - 11:20 PM

Mesoblast Limited (ASX:MSB) 2011 Chairman's Address and CEO's Presentation to Shareholders
Asia Business News - 8 minutes ago
Sydney, Nov 24, 2011 (ABN Newswire) - Mesoblast Limited (ASX:MSB) On behalf of the Board of Directors, I am very pleased to welcome you to the 2011 Annual General Meeting of Mesoblast Limited. I ...

View the full article

#93 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 23 November 2011 - 11:20 PM

Corporate Strategy Key to Mesoblast Limited (ASX:MSB) Success
Asia Business News - 3 hours ago
Melbourne, Nov 24, 2011 (ABN Newswire) - Mesoblast Limited (ASX:MSB) Chief Executive, Professor Silviu Itescu, today provided shareholders at Mesoblast's Annual General Meeting with an overview of ...
Corporate Strategy Key to Mesoblast's Success - irasia.com

View the full article

sponsored ad

  • Advert

#94 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 29 November 2011 - 01:47 PM

BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors
MarketWatch - 2 hours ago
ALAMEDA, Calif., Nov 29, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +3.45% and BioTime's subsidiary, OncoCyte Corporation, today announced they have each ...

View the full article

#95 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 01 December 2011 - 11:18 AM

People on the move: pharma jobs
In-PharmaTechnologist.com - 2 hours ago
By Natalie Morrison, 01-Dec-2011 in-PharmaTechnologist presents its round-up of the latest career moves within the world of pharmaceuticals, including news from AstraZeneca, Apricus, and BioTime ...

View the full article

#96 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 02 December 2011 - 09:26 PM

National strategy needed for regenerative medicine and cell therapy
SignOnSanDiego.com - 2 minutes ago
By Gil Van Bokkelen There is a temptation in the media to draw conclusions regarding the prospects of an entire industry sector based on a singular news event. The recent announcement by Geron ...

View the full article

#97 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 12 December 2011 - 01:46 PM

BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies
MarketWatch - 1 hour ago
ALAMEDA, Calif., Dec 12, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -0.96% , a biotechnology company that develops and markets products in the field of ...
BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies - Business Wire
BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies - TheStreet.com
4-traders- PharmiWeb.com- SunHerald.com

View the full article

#98 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 12 December 2011 - 01:45 PM


View the full article

#99 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 14 December 2011 - 08:09 PM

Shares of Biotime Fall Below Previous 52-Week Low
Financial News Network Online - Dec 14, 2011
Shares of Biotime (NYSE:BTX) traded today at $3.58, breaking its 52-week low. Approximately 125,000 shares have changed hands today, as compared to an average 30-day volume of 87,000 shares. Over ...

View the full article

#100 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 16 December 2011 - 01:59 PM

BioTime (BTX), Subsidiary Aim to Launch PanC-Dx in Europe by FY13
StreetInsider.com - 3 minutes ago
BioTime, Inc. (AMEX: BTX) and BioTime's subsidiary OncoCyte Corporation today announced plans for the development of PanC-Dx, a novel diagnostic device discovered at BioTime and OncoCyte to detect ...

View the full article

#101 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 16 December 2011 - 01:46 PM

BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-Dx™
MarketWatch - 16 minutes ago
ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX -0.27% and BioTime's subsidiary OncoCyte Corporation today announced plans for the ...
BioTime’s Subsidiary OncoCyte Corporation Announces Plans For The Novel Pan-Cancer Diagnostic Product PanC-DxTM - TheStreet.com

View the full article

#102 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 16 December 2011 - 01:46 PM

BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-Dx™
MarketWatch - 3 hours ago
ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +5.08% and BioTime's subsidiary OncoCyte Corporation today announced plans for the ...
BioTime’s Subsidiary OncoCyte Corporation Announces Plans For The Novel Pan-Cancer Diagnostic Product PanC-DxTM - TheStreet.com
BioTime (BTX), Subsidiary Aim to Launch PanC-Dx in Europe by FY13 - StreetInsider.com
PharmiWeb.com- SunHerald.com

View the full article

#103 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 19 December 2011 - 08:47 AM

Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story
Seeking Alpha - 15 minutes ago
A few weeks ago, Geron (GERN), the world's first company to conduct clinical trials using human embryonic stem cells, announced that it was halting its stem cell research to focus its research and ...

View the full article
  • dislike x 1

#104 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 19 December 2011 - 08:54 AM

A Reality Check on Three Hot Biotechs: ISTA Pharmaceuticals (ISTA), BioTime (BTX) and PharmAthene (PIP)
SmallCap Network - 3 hours ago
Do NOT buy or sell VRX, BTX, PIP, SIGA or ISTA until you have read everything. SmallCap Network provides comprehensive research and opinions on VRX, BTX, PIP, SIGA and ISTA. A closer look at ...

View the full article

#105 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 21 December 2011 - 01:39 AM

Catastrophic Success, Bio-Tec Breakthrough Technology Alert
The Market Oracle - 53 minutes ago
New readers to my musings often find it interesting, when they meet me in person, to find me quite an optimistic person, given the nature of my current predictions about the economy. And regarding ...

View the full article
  • like x 1

#106 niner

  • Guest
  • 16,276 posts
  • 1,999 ₮
  • Location:Philadelphia

Posted 21 December 2011 - 04:12 AM

This is a great article. Check it out if you have a chance.

#107 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 21 December 2011 - 01:45 PM

BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
MarketWatch - 2 hours ago
ALAMEDA, Calif., Dec 21, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +4.93% today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China ...
BIOTIME INC FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Insurance News Net
BioTime Gains Option to Use USCN Cell Lines in Cancer Dx Development - Genetic Engineering News

View the full article

#108 Elus

  • Guest
  • 793 posts
  • 723 ₮
  • Location:Interdimensional Space

Posted 21 December 2011 - 11:02 PM

Being able to do a blood test for cancer will change everything... If we can catch cancers early, we will be able to beat them so much more easily than if they were in the late stages. Combined with the potent cures mentioned in the article, and we may be seriously looking at eliminating cancer as a danger to our society.


"When the Bexion drug is administered, these nano-probes seek out phosphatidylserines and collect on the surface of cancer cells. There they trigger natural cell suicide, or apoptosis. Cancers die but healthy cells are unharmed."

"Bexion's drug has been shown effective in preclinical tests against an extraordinary range of cancers. Moreover, its seek-and-destroy mechanism could make it an ideal diagnostic tool for use in conjunction with BioTime's broad-spectrum blood test. Because a marker can be attached to the Bexion drug, it is possible to light up cancers using scanning technology, giving doctors a 3D view of neoplasms."




Holy crap...


We're slowly and surely eliminating the things that kill us... I wonder what will be after cancer, heart disease, alzheimer's, parkinson's, and the like. What sorts of disease might mitochondrial mutations/lysosomal junk produce? Makes me wonder..

#109 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 03 January 2012 - 01:46 PM

BioTime to Produce Stem Cells for Research in Muscle Disorders
MarketWatch - 2 hours ago
ALAMEDA, Calif., Jan 03, 2012 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +5.25% today announced that it has elected to market progenitors of muscle stem cells ...
BioTime (BTX) Announces Plans to Begin Producing Stem Cells for Research in Muscle Disorders - StreetInsider.com
BIOTIME, INC.: BioTime to Produce Stem Cells for Research in Muscle Disord.. - 4-traders
NASDAQ

View the full article

#110 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 03 January 2012 - 02:40 PM

BioTime Plans To Produce Stem Cells For Research In Muscle Disorders
NASDAQ - Jan 3, 2012
(RTTNews.com) - BioTime Inc. (BTX) announced Tuesday that it has elected to market progenitors of muscle stem cells bearing hereditary diseases.
BioTime to Produce Stem Cells for Research in Muscle Disorders - MarketWatch (press release)

View the full article

#111 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 21 December 2011 - 06:57 PM

BioTime Signs Deal With USCN Life Science To Source Antibody-Based Products
NASDAQ - Dec 21, 2011
(RTTNews.com) - BioTime Inc. (BTX) announced agreements with USCN Life Science, Inc.of Wuhan, China, granting BioTime an option to license USCN's antibody-producing cell lines and certain related technology that may be used by BioTime and its ...
BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products - MarketWatch (press release)

View the full article

#112 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 05 January 2012 - 03:00 AM

Australian market back in the red: Karoon Gas, WorleyParsons, Atlas Iron lead ...
Proactive Investors Australia - Jan 5, 2012
Proactive Investors is a leading financial and investor website and platform, dominating the "Small-Mid Cap" investor space with multiple investor "channels" and "touch-points.
Why the ASX's big new year rally means nothing - The Motley Fool

View the full article

#113 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 13 January 2012 - 05:43 PM

RegMed Competitive and Market Intelligence, 1/12/12, no help for the hopeful ...
Proactive Investors USA & Canada - Jan 13, 2012
Today's Gospel: RegMed stocks were under pressure … again, Thursday, following a handful of weak economic reports that … trumps investor optimism.

View the full article

#114 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 24 January 2012 - 01:45 PM


View the full article

#115 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 24 January 2012 - 04:37 PM

BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem ...
Business Wire (press release) - 17 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100.

View the full article

#116 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 01 February 2012 - 08:19 AM

MESOBLAST LIMITED : 31 January 2012 - Mesoblast Receives FDA Clearance for ...
4-traders (press release) - Feb 1, 2012
? Phase 2 clinical trial of Mesoblast's proprietary allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) in Type 2 diabetes patients cleared to commence by United States Food and Drug Administration (FDA) ?

View the full article

#117 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 31 January 2012 - 12:38 AM

FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
irasia.com (press release) - Jan 31, 2012
Results generated from this Phase 2 trial may enable Mesoblast to expand its therapeutic programs in Type 2 diabetes and metabolic diseases to address the large unmet medical needs of Type 2 diabetes patients with renal complications and the associated ...

View the full article

#118 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 17 February 2012 - 07:29 PM

BioTime CEO Michael D. West to Present at New York Stem Cell Summit
Bradenton Herald - 6 hours ago
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.

View the full article

#119 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 27 February 2012 - 02:19 AM

Half Year Results - Mesoblast Posts Strong Cash Balance
irasia.com (press release) - 32 minutes ago
Melbourne, Australia; 27 February 2012: Global regenerative medicine company, Mesoblast Limited (ASX: MSB), today reported cash reserves of $241 million for the 2012 financial half year reporting period ended 31 December 2011.

View the full article

#120 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72 ₮

Posted 08 March 2012 - 11:28 PM

BioTime to Present at ROTH 24th Annual Growth Stock Conference
SunHerald.com - 9 hours ago
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Financial Officer, Peter S. Garcia, will present a corporate overview of ...

View the full article
Back to Ventures & Markets



Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users

  1. LONGECITY
  2. → Round Table Discussion
  3. → Business
  4. → Ventures & Markets
  5. site rules